On September 27th 2018 FDA approved DCB tablets (VIZIMPROTM), for the first-line treatment of individuals suffering from metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations.17 A marketing authorization application for DCB was also accepted by the EMA (European Medicines Agency) for the same indication18. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.